Literature DB >> 34290926

Small Bowel Adenocarcinoma Mimicking a Crohn's Attack.

Arda Yavuz1, Gülnihal Ay2, Kübra Akan1, Celal Ulaşoğlu1, İlyas Tuncer1.   

Abstract

Small bowel adenocarcinoma (SBA) is a rare disease and presents with intermittent abdominal pain, weight loss, nausea, vomiting, and gastrointestinal bleeding. In cases with delayed diagnosis, intestinal obstruction or bowel perforation can also be observed. In our case, the patient presented with ileus after an operation that was diagnosed with SBA. After six cycles of chemotherapy, the patient went into complete remission.
Copyright © 2021, Yavuz et al.

Entities:  

Keywords:  colonoscopy; crohn’s disease; ileum; inflammatory bowel disease; small bowel adenocarcinoma

Year:  2021        PMID: 34290926      PMCID: PMC8289395          DOI: 10.7759/cureus.15743

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


Introduction

Small bowel adenocarcinoma (SBA) is a rare disease, the diagnosis of which remains challenging due to nonspecific symptoms that mimic Crohn's disease (CD). The predisposing diseases include Crohn's disease (8.7%), Lynch syndrome (6.9%), familial adenomatous polyposis (1.7%), celiac disease (1.7%), and Peutz-Jeghers syndrome (0.6%) [1]. Certain vital suggestions in the CD guidelines can help to detect SBA. First, all newly diagnosed patients with CD should undergo small bowel assessments (intestinal ultrasound, magnetic resonance enterography (MR enterography), and/or capsule endoscopy). Second, a patient with suspected clinical CD and a colonoscopy with normal findings should be evaluated with capsule endoscopy. Alternatively, cross-sectional imaging or device-assisted enteroscopy may be performed for endoscopic or histologic confirmation [2]. Moreover, routine surveillance is not recommended. Herein, we reported a patient with insufficient histological and endoscopic evidence of CD and was treated with mesalazine rather than undergoing further evaluation. One year after diagnosis, she developed ileus and was diagnosed with SBA. We want to emphasize the importance of small bowel assessment, especially for unresponsive treatment and an inefficient diagnostic assessment.

Case presentation

A 34-year-old woman was admitted to our emergency department with stomachache and vomiting. She was treated with mesalazine, as Crohn's disease was suspected for one year, without ulcers on her colonoscopy, and her terminal ileum biopsies were suspicious for inflammatory bowel disease (Figure 1).
Figure 1

Terminal ileum biopsy: marked architectural distortion and minimal chronic active inflammation (upper left), and normal mucosa (lower right) (HE 40X)

It was not clearly understood why the patient with follow-up at an external centre was considered a Crohn's disease. Her vital parameters were normal, and her bowel sounds were hypoactive. Air fluid was observed on imaging, and computed tomography was compatible with the ileus. Thus, a surgeon was consulted, but an operation was not considered at this time. The patient was admitted to the gastroenterology clinic for the subileus. She was followed up without nasogastric drainage because she did not accept nasogastric tube insertion. During the follow-up period, complaints of vomiting and abdominal pain continued, and the patient could not eat entirely. No findings suggestive of paralytic ileus were found in her examinations. After ten days of observation, no clinical response was observed. CT was re-evaluated, a mass image was noticed (Figure 2).
Figure 2

Dilated bowel loops and small bowel carcinoma, which was noticed later (arrow)

The decision to perform surgery was made. There was a 2cm stricture at a 60cm distance from the ileocecal valve. The diameter of the bowel was 2cm proximal and 5cm distal to the stricture. A 4.5*2.5*1.5cm tumour that invaded the subserosa and lymphovascular invasion was also observed (Figure 3, 4).
Figure 3

Normal small bowel mucosa (dark arrow) and tumor invasion in mucosa and submucosa (blank arrow) (HE 40X)

Figure 4

Tumoral invasion in muscularis propria (dark arrow) (HE 20X)

The small intestine proximal to the tumour was dilated. Microscopically there was mucosal and submucosal ulceration and skip areas. No granulomata are identified (figure 5).
Figure 5

Mucosal and submucosal ulceration (blank arrow) and skip area (dark arrow) proximal to tumor in resection specimen (HE 40X)

No loss of mismatch repair (MMR) protein expression was observed on pathological examination. Following surgery, Positron Emission Tomography - Computed Tomography (PET-CT) was performed, and focal metastases in liver segment five and two metastatic implants of 12mm and 13mm in size were observed in the left lower quadrant of the abdomen. From September 2020 to February 2021, she underwent six cycles of chemotherapy with 5-fluorouracil and oxaliplatin. After completion of chemotherapy PET-CT results were normal. Furthermore, in March 2021, a colonoscopy was performed. There was no evidence of Crohn's disease or malignancy.

Discussion

SBA represents 31%-40% of all small bowel cancer diagnoses. These primary tumors are located in the duodenum (60%), jejunum (25%-29%), and ileum (10%-13%) [3]. These are mostly diagnosed at advanced stages, such as colon carcinoma, and, despite treatment, show poor outcomes. The etiology remains unclear, but certain theories have been proposed [4]. One includes the dilution of digestive material through the small intestine and less irritation at the distal segments. This explains why two-thirds of SBAs arise in the duodenum. Second, the small bowel does not store anything, which explains why the incidence of colon carcinoma is higher than that of SBA. The small intestine plays a major role in the immune system; however, the role of gut microbiota remains unclear. The relationship between SBA and Crohn's disease remains unclear due to the statistical power of the published studies. In a recent French nationwide cohort study, the incidence of SBA was 0.235 per 1000 patient-years among patients with small bowel CD and 0.464 per 1000 patient-years among those with small-bowel CD lasting for more than eight years. Although there is a high relative risk, the absolute risk of developing small bowel cancer in patients with CD is low [5]. Distal jejunal/ileal CD localization, chronic penetrating disease, long disease duration, young age at diagnosis, male sex, steroids and immunomodulators, small bowel bypass loops, strictures, and environmental factors have been reported as risk factors [6]. However, some studies have failed to confirm these associations. Small-bowel resection and the use of aminosalicylates for more than two years are associated with a lower risk of SBA. Patients with long-standing CD and stricturing disease have the highest risk of developing SBA [7]. Advanced imaging and endoscopic techniques can facilitate the early detection of SBA, but these are not recommended because they are not cost-effective for routine surveillance. A sacculated loop with asymmetrical thickening or benign fibrostenosis-like short-segment stenosis can be seen on computed tomography or magnetic resonance imaging [8]. Capsule endoscopy can detect neoplastic lesions but does not allow for biopsy. Double-balloon enteroscopy or surgery is useful when the patient suffers from complications such as small bowel obstruction or non-responsive small bowel strictures or fistulas.

Conclusions

We report a case of a patient with SBA that presented with suspected CD but lacked significant diagnostic evidence. Further investigation led to the diagnosis of SBA, which was diagnosed at a late stage. We want to emphasize the importance of early small intestine assessment in patients who are unresponsive to treatment or when CD diagnoses are doubtful.
  8 in total

1.  Small intestinal cancer: a population-based study of incidence and survival patterns in the United States, 1992 to 2006.

Authors:  Osama Qubaiah; Susan S Devesa; Charles E Platz; Mark M Huycke; Graça M Dores
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

2.  European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies.

Authors:  Vito Annese; Laurent Beaugerie; Laurence Egan; Livia Biancone; Claus Bolling; Christian Brandts; Daan Dierickx; Reinhard Dummer; Gionata Fiorino; Jean Marc Gornet; Peter Higgins; Konstantinos H Katsanos; Loes Nissen; Gianluca Pellino; Gerhard Rogler; Franco Scaldaferri; Edyta Szymanska; Rami Eliakim
Journal:  J Crohns Colitis       Date:  2015-08-20       Impact factor: 9.071

3.  ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications.

Authors:  Christian Maaser; Andreas Sturm; Stephan R Vavricka; Torsten Kucharzik; Gionata Fiorino; Vito Annese; Emma Calabrese; Daniel C Baumgart; Dominik Bettenworth; Paula Borralho Nunes; Johan Burisch; Fabiana Castiglione; Rami Eliakim; Pierre Ellul; Yago González-Lama; Hannah Gordon; Steve Halligan; Konstantinos Katsanos; Uri Kopylov; Paulo G Kotze; Eduards Krustinš; Andrea Laghi; Jimmy K Limdi; Florian Rieder; Jordi Rimola; Stuart A Taylor; Damian Tolan; Patrick van Rheenen; Bram Verstockt; Jaap Stoker
Journal:  J Crohns Colitis       Date:  2019-02-01       Impact factor: 9.071

4.  Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients.

Authors:  Thomas Aparicio; Julie Henriques; Sylvain Manfredi; David Tougeron; Olivier Bouché; Denis Pezet; Guillaume Piessen; Romain Coriat; Aziz Zaanan; Jean-Louis Legoux; Eric Terrebone; Marc Pocard; Jean-Marc Gornet; Thierry Lecomte; Catherine Lombard-Bohas; Hervé Perrier; Cédric Lecaille; Sandrine Lavau-Denes; Dewi Vernerey; Pauline Afchain
Journal:  Int J Cancer       Date:  2020-01-22       Impact factor: 7.396

5.  Risk of colorectal cancer and small bowel adenocarcinoma in Crohn's disease: a population-based study from western Hungary 1977-2008.

Authors:  Peter Laszlo Lakatos; Gyula David; Tunde Pandur; Zsuzsanna Erdelyi; Gabor Mester; Mihaly Balogh; Istvan Szipocs; Csaba Molnar; Erzsebet Komaromi; Lajos S Kiss; Laszlo Lakatos
Journal:  J Crohns Colitis       Date:  2010-12-13       Impact factor: 9.071

6.  Incidence, presentation, and prognosis of small bowel adenocarcinoma in patients with small bowel Crohn's disease: a prospective observational study.

Authors:  Khaldoun Elriz; Fabrice Carrat; Franck Carbonnel; Lysiane Marthey; Anne Marie Bouvier; Laurent Beaugerie
Journal:  Inflamm Bowel Dis       Date:  2013-08       Impact factor: 5.325

Review 7.  Non-colorectal intestinal tract carcinomas in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (II).

Authors:  Laurence Egan; Renata D'Inca; Tine Jess; Gianluca Pellino; Franck Carbonnel; Bernd Bokemeyer; Marcus Harbord; Paula Nunes; Janneke Van der Woude; Francesco Selvaggi; John Triantafillidis
Journal:  J Crohns Colitis       Date:  2013-05-07       Impact factor: 9.071

Review 8.  The epidemiology and pathogenesis of neoplasia in the small intestine.

Authors:  David Schottenfeld; Jennifer L Beebe-Dimmer; Fawn D Vigneau
Journal:  Ann Epidemiol       Date:  2009-01       Impact factor: 3.797

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.